Cite
HARVARD Citation
Tan, E. et al. (2018). Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clinical pharmacology in drug development. 7 (5), pp. 532-542. [Online].